You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said that revenues for the third quarter is expected to be $63.1 million, which would be a 4 percent increase from the year-ago figure.
The company also disclosed that the previously announced sale of its PersonalizeDx business has been delayed after the buyer failed to complete the transaction.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
Quest is buying Shiel from Fresenius Medical Care, and it lowered its expected third quarter revenues by 1.5 percent and its EPS by $.10 on recent natural disasters.
The increase was largely due to a 13 percent rise in clinical lab revenues, driven by sales of molecular diagnostic tests, particularly in women's health.
The firm reported an 88 percent increase in product sales, but this was offset by a 79 percent drop in collaboration revenues.
Amid a flat month for the index, some firms saw large swings in their stock price. Natera led the gainers, while NantHealth led the decliners.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
The company also said that net income for the first half of 2017 rose 18 percent year over year to €101 million from €85.7 million.
The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.